General News

Vasomotor Symptoms of Menopause Market Expected to Witness a Sustainable Growth by 2024

Menopause is the stage during which women stop producing ovaries and there is an end of the fertile phase. It occurs in 85% of premenopausal women during their late 40s, resulting in the cessation of their menstrual cycle. Due to the cessation of menstrual flow, the production of estrogen decreases and gonadotropin increases, which gives rise to various physiological and psychological changes, called vasomotor symptoms.

View Report –

https://www.transparencymarketresearch.com/vasomotor-symptoms-menopause-market.html

Vasomotor symptoms of menopause are the actions which are related to nerves and muscles that cause the blood vessels to dilate. Vasomotor symptoms of menopause are basically a transition between two phases: perimenopause and menopause. There are various therapies related to vasomotor symptoms of menopause and henceforth the market can be segmented as follows:

Hormone Replacement Therapy (HRT): HRT is a hormone therapy which is given to women whose estrogen and progesterone hormone level have dropped enormously

Selective estrogen receptor modulators (SERM): SERMs are a type of drugs that block the effect of estrogen in the breast cells and activate the action of estrogen in other cells such as uterine cells

Gabapentin: They are a type of medications which reduces the effect of hot flash and night sweats

Antidepressants: Few vasomotor symptoms are relieved with the aid of antidepressants. Example: fluoxetine and venlafaxine.

Request to View Brochure of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=15731

The driving factors that will augment the growth of menopausal symptoms therapeutics market are introduction of new treatments and therapies in the market, increasing awareness among female patients about their health and use of non-hormonal therapies.

Geographically, North America dominates the menopause therapeutics market followed by Europe. According to NutritionMD, about 40% of North American women seek treatment for menopausal symptoms. Increasing cases of menopausal symptoms and the rising need of women population to go for novel therapies are the major factors, which have driven the growth of the menopausal symptoms therapeutic market.

Asia-Pacific is one of the most rapidly developing region and the prime factors that will drive the growth of menopausal symptoms therapeutics market in this region are increasing geriatric female population with menopause disorders, and a shift in preference from hormonal therapies to non-hormonal therapies that will create an opportunity for many pharmaceutical companies to develop novel technologies and therapies.

Request to View ToC of the report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=15731

Some of the top market players of this market are Eli Lilly and Company. Procter & Gamble, Pfizer Inc., Ausio harmaceuticals, LLC, EndoCeutics, Inc., Edgemont Pharmaceuticals, LLC and many others.